{"favorite_id": 3974, "calc_type": "calculator", "dosing": false, "full_title_en": "TNM Staging for Melanoma", "short_title_en": "TNM Melanoma Staging", "medium_description_en": "Stages melanoma based on tumor, lymph nodes, and metastases.", "short_description_en": "Melanoma staging.", "before_use": "", "instructions_en": "<p>This calculator is based on the 7th edition of the AJCC Cancer Staging Manual. The <calculator id=\"10113\">8th edition</calculator> is now recommended for use over this version.</p>", "purpose_en": ["Prognosis"], "disease_en": ["Cancer", "Chemotherapy", "Skin Cancer", "Melanoma"], "specialty_en": ["Dermatology", "Hematology and Oncology", "Surgery (General)"], "chief_complaint_en": ["Lymphadenopathy", "Mass", "Pain", "Rash"], "system_en": ["Dermatologic", "Oncologic"], "search_abbreviation_en": ["TNM Melanoma", "melanoma", "skin cancer", "tumor", "tumour", "lymph nodes", "lymphadenectomy", "survival", "stage", "cancer", "LDH"], "slug": "tnm-staging-melanoma", "seo": {"meta_description_en": "TNM Staging for Melanoma stages melanoma based on tumor depth, lymph node involvement, and metastasis characteristics.", "keywords_en": "Tnm, melanoma, skin cancer staging, abcd, abcde, 7 point checklist, malignant melanoma"}, "content": {"how_to_use": {"use_case_en": "<p><span>Patients with confirmed melanoma diagnosed by biopsy.</span></p>", "pearls_pitfalls_en": "<ul> <li><span>Requires pathologic specimen for evaluation, so lymph node status cannot be adequately assessed until after surgical resection. </span></li> <li><span>TNM staging is frequently updated based on new evidence. The AJCC 8th edition is expected to be implemented into clinical practice on January 1, 2018. Until then, all tumors should be staged according to the 7th edition.</span></li> </ul>", "why_use_en": "<p><span>TNM staging is the standard staging system used by surgeons, medical oncologists, and dermatologists to prognosticate and communicate about patients.</span></p>"}, "next_steps": {"advice_en": "<p><span>National Comprehensive Cancer Network (NCCN) guidelines use TNM staging for biopsy-confirmed cases of melanoma.</span></p>", "management_en": "<p><span>All patients with biopsy-confirmed melanoma should be referred to a surgeon and/or medical oncologist.</span></p>", "critical_actions_en": "<ul> <li>Per <a href=\"https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#melanoma\" target=\"\u201d_blank\u201d\">NCCN guidelines</a>, when the sentinel lymph node is positive, complete lymph node dissection should be discussed.</li> <ul> <li>When the sentinel lymph node is positive by pathology only, systemic imaging is indicated to evaluate specific signs or symptoms.</li> <li>When the sentinel lymph node is clinically positive, systemic imaging should be performed for baseline staging.</li> </ul> </ul>"}, "about": {"formula_en": "<div class=\"table-responsive\"> <table class=\"table table-bordered\"> <tbody> <tr> <td colspan=\"4\"> <p><strong>Primary tumor (T)</strong></p> </td> </tr> <tr> <td> <p>Tx</p> </td> <td colspan=\"3\"> <p>Cannot be assessed (e.g. curettaged or severely regressed melanoma)</p> </td> </tr> <tr> <td> <p>T0</p> </td> <td colspan=\"3\"> <p>No evidence of primary tumor</p> </td> </tr> <tr> <td> <p>Tis</p> </td> <td colspan=\"3\"> <p>Melanoma in situ</p> </td> </tr> <tr> <td> <p>T1</p> </td> <td> <p>Thickness \u22641.0 mm</p> </td> <td colspan=\"2\"> <p>T1a: no ulceration and mitosis &lt;1/mm<sup>2</sup></p> <p>T1b: ulceration or mitoses \u22651/mm<sup>2</sup></p> </td> </tr> <tr> <td> <p>T2</p> </td> <td> <p>Thickness 1.01\u20132.0 mm</p> </td> <td colspan=\"2\"> <p>T2a: no ulceration</p> <p>T2b: ulceration</p> </td> </tr> <tr> <td> <p>T3</p> </td> <td> <p>Thickness 2.01\u20134.0 mm</p> </td> <td colspan=\"2\"> <p>T3a: no ulceration</p> <p>T3b: ulceration</p> </td> </tr> <tr> <td> <p>T4</p> </td> <td> <p>Thickness &gt;4.0 mm</p> </td> <td colspan=\"2\"> <p>T4a: no ulceration</p> <p>T4b: ulceration</p> </td> </tr> <tr> <td colspan=\"4\"> <p><strong>Regional lymph nodes (N)</strong></p> </td> </tr> <tr> <td> <p>Nx</p> </td> <td colspan=\"3\"> <p>Cannot be assessed</p> <p>(e.g. previously removed for other reason)</p> </td> </tr> <tr> <td> <p>N0</p> </td> <td colspan=\"3\"> <p>No regional metastases detected</p> </td> </tr> <tr> <td> <p>N1</p> </td> <td> <p>1 node</p> </td> <td colspan=\"2\"> <p>N1a: micrometastasis<sup>1</sup></p> <p>N1b: macrometastasis<sup>2</sup></p> </td> </tr> <tr> <td> <p>N2</p> </td> <td> <p>2\u20133 nodes</p> </td> <td colspan=\"2\"> <p>N2a: micrometastasis<sup>1</sup></p> <p>N2b: macrometastasis<sup>2</sup></p> <p>N2c: in transit met(s) or satellite(s) without metastatic nodes</p> </td> </tr> <tr> <td> <p>N3</p> </td> <td> <p>\u22654 metastatic nodes, or matted nodes, or in transit met(s) or satellites with metastatic nodes</p> </td> <td colspan=\"2\"><br><br><br><br></td> </tr> <tr> <td colspan=\"4\"> <p><strong>Distant metastasis (M)</strong></p> </td> </tr> <tr> <td> <p>M0</p> </td> <td colspan=\"3\"> <p>No detectable evidence of distant metastases and normal serum LDH</p> </td> </tr> <tr> <td> <p>M1a</p> </td> <td colspan=\"3\"> <p>Metastases to skin, subcutaneous, or distant lymph nodes and normal serum LDH</p> </td> </tr> <tr> <td> <p>M1b</p> </td> <td colspan=\"3\"> <p>Lung metastases and normal serum LDH</p> </td> </tr> <tr> <td> <p>M1c</p> </td> <td colspan=\"3\"> <p>Metastases to all other visceral sites with normal serum LDH, or distant metastases to any site with elevated serum LDH</p> </td> </tr> </tbody> </table> </div> <p>1. Diagnosed after sentinel lymph node biopsy and completion lymphadenectomy (if performed).</p> <p><br>2. Clinically detectable nodal metastases confirmed by therapeutic lymphadenectomy or when nodal metastasis exhibits gross extracapsular extension.</p>", "more_info_en": "<div class=\"table-responsive\"> <p>Interpretation:</p> <table> <tbody> <tr> <td colspan=\"8\"> <p><strong>Anatomic stage / prognostic groups</strong></p> </td> </tr> <tr> <td colspan=\"4\"> <p>Clinical staging<sup>3</sup></p> </td> <td colspan=\"4\"> <p>Pathologic staging<sup>4</sup></p> </td> </tr> <tr> <td> <p><strong>Stage 0</strong></p> </td> <td> <p>Tis</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p><strong>0</strong></p> </td> <td> <p>Tis</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p><strong>Stage IA</strong></p> </td> <td> <p>T1a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p><strong>IA</strong></p> </td> <td> <p>T1a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td rowspan=\"2\"> <p><strong>Stage IB</strong></p> </td> <td> <p>T1b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td rowspan=\"2\"> <p><strong>IB</strong></p> </td> <td> <p>T1b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p>T2a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p>T2a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td rowspan=\"2\"> <p><strong>Stage IIA</strong></p> </td> <td> <p>T2b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td rowspan=\"2\"> <p><strong>IIA</strong></p> </td> <td> <p>T2b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p>T3a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p>T3a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p><strong>Stage IIB</strong></p> </td> <td> <p>T3b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td rowspan=\"2\"> <p><strong>IIB</strong></p> </td> <td> <p>T3b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td> <p>T4a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p>T4a</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p><strong>Stage IIC</strong></p> </td> <td> <p>T4b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> <td> <p><strong>IIC</strong></p> </td> <td> <p>T4b</p> </td> <td> <p>N0</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p><strong>Stage III</strong></p> </td> <td> <p>Any T</p> </td> <td> <p>\u2265N1</p> </td> <td> <p>M0</p> </td> <td rowspan=\"2\"> <p><strong>IIIA</strong></p> </td> <td> <p>T(1-4)a</p> </td> <td> <p>N1a</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td rowspan=\"10\">&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)a</p> </td> <td> <p>N2a</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td rowspan=\"5\"> <p><strong>IIIB</strong></p> </td> <td> <p>T(1-4)b</p> </td> <td> <p>N1a</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)b</p> </td> <td> <p>N2a</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)a</p> </td> <td> <p>N1b</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)a</p> </td> <td> <p>N2b</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)a</p> </td> <td> <p>N2c</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td rowspan=\"4\"> <p><strong>IIIC</strong></p> </td> <td> <p>T(1-4)b</p> </td> <td> <p>N1b</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)b</p> </td> <td> <p>N2b</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>T(1-4)b</p> </td> <td> <p>N2c</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td> <p>Any T</p> </td> <td> <p>N3</p> </td> <td> <p>M0</p> </td> </tr> <tr> <td> <p><strong>Stage IV</strong></p> </td> <td> <p>Any T</p> </td> <td> <p>Any N</p> </td> <td> <p>M1</p> </td> <td> <p><strong>IV</strong></p> </td> <td> <p>Any T</p> </td> <td> <p>Any N</p> </td> <td> <p>M1</p> </td> </tr> </tbody> </table> <p><span>3. Clinical staging includes microstaging of the primary melanoma and clinical/radiologic evaluation for metastases. By convention, it should&nbsp;</span>be used after complete excision of the primary melanoma with clinical assessment for regional and distant metastases.</p> <p><span>4. Pathologic staging includes microstaging of the primary melanoma and pathologic information about the regional lymph nodes after partial or complete lymphadenectomy. Pathologic Stage 0 or Stage IA patients are the exception; they do not require pathologic evaluation of their lymph nodes.</span></p> </div>", "evidence_based_medicine_en": "", "references_list": {"Original/Primary Reference": [{"text": "Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. Melanoma of the skin. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer-Verlag; 2010."}], "Other References": [{"href": "", "text": ""}], "Validation": [{"href": "", "text": ""}], "Clinical Practice Guidelines": [{"href": "https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#melanoma", "text": "NCCN Clinical Practice Guidelines in Oncology: Melanoma. V.1. 2017."}], "Manufacturer Website": [{"href": "", "text": ""}], "Outcomes": [{"href": "", "text": ""}]}}, "contributor": {"expert_name": [{"description": "", "firstName": "Allison", "img": "", "lastName": "Warner", "name": "Allison Betof Warner, MD, PhD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "reviewer": {"expert_name": [{"name": "Michael Postow, MD"}]}, "creator": [{"name": "Dr. Daniel G. Coit", "creator_info": {"about_en": "<p>Daniel G. Coit, MD, FACS, is a surgical oncologist at Memorial Sloan Kettering Cancer Center. He is also a co-leader of the Melanoma Disease Management Team. Dr. Coit\u2019s research interests include identifying high risk patients for melanoma recurrence and gastric cancer.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-daniel-g-coit.jpg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Coit+DG%5BAuthor%5D"}}], "related_resources": {"mdcalc_rating": {"evidence": "", "clinical": "", "popularity": ""}, "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "radio", "label_en": "Primary tumor (T)", "name": "pritumor", "options": [{"label": "No evidence of primary tumor", "value": 0}, {"label": "Melanoma in situ", "value": -2}, {"label": "Thickness \u22641.0 mm", "value": 1}, {"label": "Thickness 1.01\u20132.0 mm", "value": 2}, {"label": "Thickness 2.01\u20134.0 mm", "value": 3}, {"label": "Thickness >4.0 mm", "value": 4}, {"label": "Cannot be assessed (e.g. curettaged or severely regressed melanoma)", "value": -1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Ulceration or mitosis", "name": "t1", "options": [{"label": "No ulceration and mitosis <1/mm<sup>2</sup>", "value": 0}, {"label": "Ulceration or mitosis \u22651/mm<sup>2</sup>", "value": 1}], "conditionality": "pritumor == 1", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Ulceration", "name": "t234", "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "conditionality": "pritumor == 2 || pritumor == 3 || pritumor == 4", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Regional lymph nodes (N)", "name": "rlnodes", "options": [{"label": "No regional metastases detected", "value": 0}, {"label": "1 node", "value": 1}, {"label": "2\u20133 nodes", "value": 2}, {"label": "\u22654 metastatic nodes, or matted nodes, or in transit met(s) or satellites with metastatic nodes", "value": 3}, {"label": "Cannot be assessed (e.g. previously removed for other reason)", "value": -1}], "conditionality": "", "show_points": false, "optional": false}, {"type": "toggle", "label_en": "Micro or macro", "name": "n1", "options": [{"label": "Micrometastasis", "value": 0}, {"label": "Macrometastasis", "value": 1}], "conditionality": "rlnodes == 1", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Micro or macro", "name": "n2", "options": [{"label": "Micrometastasis", "value": 0}, {"label": "Macrometastasis", "value": 1}, {"label": "In transit met(s) or satellite(s) without metastatic nodes", "value": 2}], "conditionality": "rlnodes == 2", "show_points": false, "optional": false}, {"type": "radio", "label_en": "Distant metastasis (M)", "name": "distmeta", "options": [{"label": "No detectable evidence of distant metastases and normal serum LDH", "value": 0}, {"label": "Metastases to skin, subcutaneous, or distant lymph nodes and normal serum LDH", "value": 1}, {"label": "Lung metastases and normal serum LDH", "value": 2}, {"label": "Metastases to all other visceral sites with normal serum LDH, or distant metastases to any site with elevated serum LDH", "value": 3}], "conditionality": "", "show_points": false, "optional": false}], "md5": "f8ea315a75237fb85ee50c2dcd196b2e", "related_calcs": [{"calcId": 10113, "short_title_en": "TNM Melanoma Staging (8th Ed.)", "slug": "tnm-staging-melanoma-8th-edition"}, {"calcId": 10116, "short_title_en": "TNM HCC Staging (8th Ed.)", "slug": "tnm-staging-hepatocellular-carcinoma-hcc-8th-edition"}, {"calcId": 10122, "short_title_en": "TNM RCC Staging (8th Ed.)", "slug": "tnm-staging-renal-cell-carcinoma-rcc-8th-edition"}]}